Having trouble accessing articles? Reset your cache.

Oral anti-CD3 mAb: Phase IIa started

NasVax began a single-blind, placebo-controlled, Israeli Phase IIa trial to evaluate once-daily 0.2,

Read the full 138 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE